ArticleMedicine2026
Associations of the magnesium depletion score with the prevalence and mortality of chronic respiratory diseases: Analyses of NHANES 2003-2018.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic respiratory diseases (CRDs) remain a substantial global health burden. The magnesium depletion score (MDS) integrates clinical factors associated with magnesium loss, but its associations with CRD prevalence and mortality remain unclear. We examined these associations in a nationally representative sample of US adults. We conducted a cross-sectional prevalence analysis and a prospective mortality analysis using data from the National Health and Nutrition Examination Survey (NHANES) 2003-2018. CRDs were defined by self-reported physician diagnoses of asthma, chronic obstructive pulmonary disease, chronic bronchitis, or emphysema. Survey-weighted logistic and Cox regression examined CRD prevalence and all-cause mortality, respectively. Additional analyses included subgroup analyses, receiver operating characteristic (ROC) curves, and survival Shapley additive explanations. Among 30,044 participants, 5588 had CRDs. Compared with MDS = 0, the fully adjusted odds ratios for CRD prevalence were 1.17 (95% confidence interval [CI], 1.04-1.32), 1.27 (95% CI, 1.10-1.48), and 1.34 (95% CI, 1.11-1.62) for MDS = 1, MDS = 2, and MDS ≥3, respectively. Exploratory interaction tests were significant for race, systemic immune-inflammation index, and poverty-income ratio. Among 5581 participants with CRDs, MDS ≥3 was associated with higher all-cause mortality (hazard ratio, 1.59; 95% CI, 1.06-2.37), whereas lower MDS categories were not. MDS alone yielded time-dependent area under the curves ranging from 0.734 to 0.778, while its contribution within the multivariable survival model showed an overall increasing trend across MDS values. Higher MDS was associated with greater CRD prevalence, and MDS ≥3 was associated with higher all-cause mortality among participants with CRDs. Prospective studies incorporating direct measures of magnesium status and clinically validated respiratory outcomes are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.